Database Query Results : , , VEGFR2

VEGFR2, Vascular Endothelial Growth Factor Receptor 2: Click to Expand ⟱
Source:
Type: receptor tyrosine kinase
VEGFR2 is a receptor tyrosine kinase that plays a crucial role in angiogenesis, the process of new blood vessel formation. In cancer, VEGFR2 is often overexpressed, promoting the growth of new blood vessels that supply the tumor with oxygen and nutrients, facilitating its growth and metastasis.
Inhibiting VEGFR2 signaling has been shown to be an effective strategy in cancer therapy, and several VEGFR2 inhibitors have been approved for the treatment of various types of cancer, including renal cell carcinoma, colorectal cancer, and non-small cell lung cancer. These inhibitors work by blocking the binding of VEGF to VEGFR2, thereby inhibiting angiogenesis and tumor growth.
Scientific Papers found: Click to Expand⟱
2660- AL,    Allicin: A review of its important pharmacological activities
- Review, AD, NA - Review, Var, NA - Review, Park, NA - Review, Stroke, NA
*Inflam↓, AntiCan↑, *antiOx↑, *cardioP↑, *hepatoP↑, *BBB↑, *Half-Life↝, *H2S↑, *BP↓, *neuroP↑, *cognitive↑, *neuroP↑, *ROS↓, *GutMicro↑, *LDH↓, *ROS↓, *lipid-P↓, *antiOx↑, *other↑, *PI3K↓, *Akt↓, *NF-kB↓, *NO↓, *iNOS↓, *PGE2↓, *COX2↓, *IL6↓, *TNF-α↓, *MPO↓, *eff↑, *NRF2↑, *Keap1↓, *TBARS↓, *creat↓, *LDH↓, *AST↓, *ALAT↓, *MDA↓, *SOD↑, *GSH↑, *GSTs↑, *memory↑, chemoP↑, IL8↓, Cyt‑c↑, Casp3↑, Casp8↑, Casp9↑, Casp12↑, p38↑, Fas↑, P53↑, P21↑, CHK1↓, CycB/CCNB1↓, GSH↓, ROS↑, TumCCA↑, Hif1a↓, Bcl-2↓, VEGF↓, TumCMig↓, STAT3↓, VEGFR2↓, p‑FAK↓,
958- Api,    Apigenin suppresses tumor angiogenesis and growth via inhibiting HIF-1α expression in non-small cell lung carcinoma
- in-vitro, Lung, NCIH1299
Hif1a↓, VEGF↓, VEGFR2↓, PDGF↓, angioG↓,
3383- ART/DHA,    Dihydroartemisinin: A Potential Natural Anticancer Drug
- Review, Var, NA
TumCP↓, Apoptosis↑, TumMeta↓, angioG↓, TumAuto↑, ER Stress↑, ROS↑, Ca+2↑, p38↑, HSP70/HSPA5↓, PPARγ↑, GLUT1↓, Glycolysis↓, PI3K↓, Akt↓, Hif1a↓, PKM2↓, lactateProd↓, GlucoseCon↓, EMT↓, Slug↓, Zeb1↓, ZEB2↓, Twist↓, Snail?, CAFs/TAFs↓, TGF-β↓, p‑STAT3↓, M2 MC↓, uPA↓, HH↓, AXL↓, VEGFR2↓, JNK↑, Beclin-1↑, GRP78/BiP↑, eff↑, eff↑, eff↑, eff↑, eff↑, eff↑, IL4↓, DR5↑, Cyt‑c↑, Fas↑, FADD↑, cl‑PARP↑, cycE/CCNE↓, CDK2↓, CDK4↓, Mcl-1↓, Ki-67↓, Bcl-2↓, CDK6↓, VEGF↓, COX2↓, MMP9↓,
2617- Ba,    Potential of baicalein in the prevention and treatment of cancer: A scientometric analyses based review
- Review, Var, NA
Ca+2↑, MMP2↓, MMP9↓, Vim↓, Snail↓, E-cadherin↑, Wnt↓, β-catenin/ZEB1↓, p‑Akt↓, p‑mTOR↓, NF-kB↓, i-ROS↑, Bcl-2↓, BAX↑, Cyt‑c↑, Casp3↑, Casp9↑, STAT3↓, IL6↓, MMP2↓, MMP9↓, NOTCH↓, PPARγ↓, p‑NRF2↓, HK2↓, LDHA↓, PDK1↓, Glycolysis↓, PTEN↑, Akt↓, Hif1a↓, MMP↓, VEGF↓, VEGFR2↓, TOP2↓, uPA↓, TIMP1↓, TIMP2↓, cMyc↓, TrxR↓, ASK1↑, Vim↓, ZO-1↑, E-cadherin↑, SOX2↓, OCT4↓, Shh↓, Smo↓, Gli1↓, N-cadherin↓, XIAP↓,
1299- BBR,    Effects of Berberine and Its Derivatives on Cancer: A Systems Pharmacology Review
- Review, NA, NA
TumCCA↑, TP53↑, COX2↓, Bax:Bcl2↑, ROS↑, VEGFR2↓, Akt↓, ERK↓, MMP2↓, MMP9↓, IL8↑, P21↑, p27↑, E-cadherin↓, Fibronectin↓, cMyc↓,
2686- BBR,    Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs
- Review, Nor, NA
Inflam↓, IL6↓, MCP1↓, COX2↓, PGE2↓, MMP2↓, MMP9↓, DNAdam↑, eff↝, Telomerase↓, Bcl-2↓, AMPK↑, ROS↑, MMP↓, ATP↓, p‑mTORC1↓, p‑S6K↓, ERK↓, PI3K↓, PTEN↑, Akt↓, Raf↓, MEK↓, Dose↓, Dose↑, selectivity↑, TumCCA↑, eff↑, EGFR↓, Glycolysis↓, Dose?, p27↑, CDK2↓, CDK4↓, cycD1/CCND1↓, cycE/CCNE↓, Bax:Bcl2↑, Casp3↑, Casp9↑, VEGFR2↓, ChemoSen↑, eff↑, eff↑, PGE2↓, JAK2↓, STAT3↓, CXCR4↓, CCR7↓, uPA↓, CSCs↓, EMT↓, Diff↓, CD133↓, Nestin↓, n-MYC↓, NOTCH↓, SOX2↓, Hif1a↓, VEGF↓, RadioS↑,
2775- Bos,    The journey of boswellic acids from synthesis to pharmacological activities
- Review, Var, NA - Review, AD, NA - Review, PSA, NA
ROS↑, ER Stress↑, TumCG↓, Apoptosis↑, Inflam↓, ChemoSen↑, Casp↑, ERK↓, cl‑PARP↑, AR↓, cycD1/CCND1↓, VEGFR2↓, CXCR4↓, radioP↑, NF-kB↓, VEGF↓, P21↑, Wnt↓, β-catenin/ZEB1↓, Cyt‑c↑, MMP2↓, MMP1↓, MMP9↓, PI3K↓, MAPK↓, JNK↑, *5LO↓, *NRF2↑, *HO-1↑, *MDA↓, *SOD↑, *hepatoP↑, *ALAT↓, *AST↓, *LDH↑, *CRP↓, *COX2↓, *GSH↑, *ROS↓, *Imm↑, *Dose↝, *eff↑, *neuroP↑, *cognitive↑, *IL6↓, *TNF-α↓,
3869- Carno,    Carnosine, Small but Mighty—Prospect of Use as Functional Ingredient for Functional Food Formulation
- Review, AD, NA - Review, Stroke, NA
*ROS↓, *IronCh↑, *AntiAge↑, *antiOx↑, *Inflam↓, *neuroP↑, *lipid-P↓, *toxicity↓, *NOX4↓, *SOD↑, *HNE↓, *IL6↓, *TNF-α↓, *IL1β↓, *Sepsis↓, *eff↑, *GABA↝, *Aβ↓, Glycolysis↓, AntiTum↑, p‑Akt↓, TumCCA↑, angioG↓, VEGFR2↓, NF-kB↓,
1621- EA,    The multifaceted mechanisms of ellagic acid in the treatment of tumors: State-of-the-art
- Review, Var, NA
AntiCan↑, Apoptosis↑, TumCP↓, TumMeta↓, TumCI↓, TumAuto↑, VEGFR2↓, MAPK↓, PI3K↓, Akt↓, PD-1↓, NOTCH↓, PCNA↓, Ki-67↓, cycD1/CCND1↓, CDK2↑, CDK6↓, Bcl-2↓, cl‑PARP↑, BAX↑, Casp3↑, DR4↑, DR5↑, Snail↓, MMP2↓, MMP9↓, TGF-β↑, PKCδ↓, β-catenin/ZEB1↓, SIRT1↓, HO-1↓, ROS↑, CHOP↑, Cyt‑c↑, MMP↓, OCR↓, AMPK↑, Hif1a↓, NF-kB↓, E-cadherin↑, Vim↓, EMT↓, LC3II↑, CIP2A↓, GLUT1↓, PDH↝, MAD↓, LDH↓, GSTs↑, NOTCH↓, survivin↓, XIAP↓, ER Stress↑, ChemoSideEff↓, ChemoSen↑,
1618- EA,    A comprehensive review on Ellagic acid in breast cancer treatment: From cellular effects to molecular mechanisms of action
- Review, BC, NA
TumCCA↑, TumCMig↓, TumCI↓, TumMeta↓, Apoptosis↑, TGF-β↓, SMAD3↓, CDK6↓, PI3K↓, Akt↓, angioG↓, VEGFR2↓, MAPK↓, NEDD9↓, NF-kB↓, eff↑, eff↑, RadioS↑, ChemoSen↑, DNAdam↑, eff↑, *toxicity∅, *toxicity∅,
643- EGCG,    New insights into the mechanisms of polyphenols beyond antioxidant properties; lessons from the green tea polyphenol, epigallocatechin 3-gallate
- Analysis, NA, NA
H2O2↑, Fenton↑, PDGFR-BB↑, EGFR↓, VEGFR2↓, IGFR↓, Ca+2↑, NO↑, Sp1/3/4↓, NF-kB↓, AP-1↓, STAT1↓, STAT3↓, FOXO↓, mtDam↑, TumAuto↑,
684- EGCG,    Improving the anti-tumor effect of EGCG in colorectal cancer cells by blocking EGCG-induced YAP activation
- in-vitro, CRC, NA
eff↑, Akt↓, VEGFR2↓, STAT3↓, P53↓, Hippo↓, YAP/TEAD↑,
2827- FIS,    The Potential Role of Fisetin, a Flavonoid in Cancer Prevention and Treatment
- Review, Var, NA
*antiOx↑, *Inflam↓, neuroP↑, hepatoP↑, RenoP↑, cycD1/CCND1↓, TumCCA↑, MMPs↓, VEGF↓, MAPK↓, NF-kB↓, angioG↓, Beclin-1↑, LC3s↑, ATG5↑, Bcl-2↓, BAX↑, Casp↑, TNF-α↓, Half-Life↓, MMP↓, mt-ROS↑, cl‑PARP↑, CDK2↓, CDK4↓, Cyt‑c↑, Diablo↑, DR5↑, Fas↑, PCNA↓, Ki-67↓, p‑H3↓, chemoP↑, Ca+2↑, Dose↝, CDC25↓, CDC2↓, CHK1↑, Chk2↑, ATM↑, PCK1↓, RAS↓, p‑p38↓, Rho↓, uPA↓, MMP7↓, MMP13↓, GSK‐3β↑, E-cadherin↑, survivin↓, VEGFR2↓, IAP2↓, STAT3↓, JAK1↓, mTORC1↓, mTORC2↓, NRF2↑,
1241- Ge,  PACs,    Grape seed proanthocyanidins inhibit angiogenesis via the downregulation of both vascular endothelial growth factor and angiopoietin signaling
- in-vitro, Nor, NA
*VEGF↓, *MMP2↓, *MMP9↓, *p‑VEGFR2↓,
2864- HNK,    Honokiol: A Review of Its Anticancer Potential and Mechanisms
- Review, Var, NA
TumCCA↑, CDK2↓, EMT↓, MMPs↓, AMPK↑, TumCI↓, TumCMig↓, TumMeta↓, VEGFR2↓, *antiOx↑, *Inflam↓, *BBB↑, *neuroP↑, *ROS↓, Dose↝, selectivity↑, Casp3↑, Casp9↑, NOTCH1↓, cycD1/CCND1↓, cMyc↓, P21?, DR5↑, cl‑PARP↑, P53↑, Mcl-1↑, p65↓, NF-kB↓, ROS↑, JNK↑, NRF2↑, cJun↑, EF-1α↓, MAPK↓, PI3K↓, mTORC1↓, CSCs↓, OCT4↓, Nanog↓, SOX4↓, STAT3↓, CDK4↓, p‑RB1↓, PGE2↓, COX2↓, β-catenin/ZEB1↑, IKKα↓, HDAC↓, HATs↑, H3↑, H4↑, LC3II↑, c-Raf↓, SIRT3↑, Hif1a↓, ER Stress↑, GRP78/BiP↑, cl‑CHOP↑, MMP↓, PCNA↓, Zeb1↓, NOTCH3↓, CD133↓, Nestin↓, ATG5↑, ATG7↑, survivin↓, ChemoSen↑, SOX2↓, OS↑, P-gp↓, Half-Life↓, Half-Life↝, eff↑, BioAv↓,
4640- HT,    The anti-cancer potential of hydroxytyrosol
- Review, Var, NA
selectivity↑, MMP↓, Cyt‑c↑, Casp9↑, Casp3↑, Bcl-2↓, BAX↑, MPT↑, Fas↑, PI3K↓, Akt↓, mTOR↓, Mcl-1↓, survivin↓, STAT3↓, EMT↓, TumCI↓, angioG↓, E-cadherin↑, N-cadherin↓, Snail↓, Twist↓, MMPs↓, MMP2↓, MMP9↓, VEGF↓, VEGFR2↓, Hif1a↓, CSCs↓, CD44↓, Wnt↓, β-catenin/ZEB1↓,
2914- LT,    Therapeutic Potential of Luteolin on Cancer
- Review, Var, NA
*antiOx↑, *IronCh↑, *toxicity↓, *BioAv↓, *BioAv↑, DNAdam↑, TumCP↓, DR5↑, P53↑, JNK↑, BAX↑, cl‑Casp3↑, cl‑Casp8↑, cl‑Casp9↑, cl‑PARP↑, survivin↓, cycD1/CCND1↓, CycB/CCNB1↓, CDC2↓, P21↑, angioG↓, MMP2↓, AEG1↓, VEGF↓, VEGFR2↓, MMP9↓, CXCR4↓, PI3K↓, Akt↓, ERK↓, TumAuto↑, LC3B-II↑, EMT↓, E-cadherin↑, N-cadherin↓, Wnt↓, ROS↑, NICD↓, p‑GSK‐3β↓, iNOS↓, COX2↓, NRF2↑, Ca+2↑, ChemoSen↑, ChemoSen↓, IFN-γ↓, RadioS↑, MDM2↓, NOTCH1↓, AR↓, TIMP1↑, TIMP2↑, ER Stress↑, CDK2↓, Telomerase↓, p‑NF-kB↑, p‑cMyc↑, hTERT/TERT↓, RAS↓, YAP/TEAD↓, TAZ↓, NF-kB↓, NRF2↓, HO-1↓, MDR1↓,
2906- LT,    Luteolin, a flavonoid with potentials for cancer prevention and therapy
- Review, Var, NA
*Inflam↓, AntiCan↑, antiOx⇅, Apoptosis↑, TumCP↓, TumMeta↓, angioG↓, PI3K↓, Akt↓, NF-kB↓, XIAP↓, P53↑, *ROS↓, *GSTA1↑, *GSR↑, *SOD↑, *Catalase↑, *other↓, ROS↑, Dose↝, chemoP↑, NF-kB↓, JNK↑, p27↑, P21↑, DR5↑, Casp↑, Fas↑, BAX↑, MAPK↓, CDK2↓, IGF-1↓, PDGF↓, EGFR↓, PKCδ↓, TOP1↓, TOP2↓, Bcl-xL↓, FASN↓, VEGF↓, VEGFR2↓, MMP9↓, Hif1a↓, FAK↓, MMP1↓, Twist↓, ERK↓, P450↓, CYP1A1↓, CYP1A2↓, TumCCA↑,
972- MAG,    Magnolol suppresses hypoxia-induced angiogenesis via inhibition of HIF-1α/VEGF signaling pathway in human bladder cancer cells
- vitro+vivo, Bladder, T24
angioG↓, VEGF↓, H2O2↓, Hif1a↓, VEGFR2↓, Akt↓, mTOR↓, P70S6K↓, 4E-BP1↓, TumCG↓, CD31↓, CA↓,
3482- MF,    Pulsed Electromagnetic Fields Increase Angiogenesis and Improve Cardiac Function After Myocardial Ischemia in Mice
- in-vitro, NA, NA
*cardioP↑, *VEGF↑, *VEGFR2↑, *Hif1a↑, *FGF↑, *ITGB1↑, *angioG↑,
3464- MF,    Progressive Study on the Non-thermal Effects of Magnetic Field Therapy in Oncology
- Review, Var, NA
AntiTum↑, TumCG↓, TumCCA↑, Apoptosis↑, TumAuto↑, Diff↑, angioG↓, TumMeta↓, EPR↑, ChemoSen↑, ROS↑, DNAdam↑, P53↑, Akt↓, MAPK↑, Casp9↑, VEGFR2↓, P-gp↓,
524- MF,    Inhibition of Angiogenesis Mediated by Extremely Low-Frequency Magnetic Fields (ELF-MFs)
- vitro+vivo, PC, MS-1 - vitro+vivo, PC, HUVECs
other↓, TumCP↓, TumCMig↓, VEGFR2↓, TumVol↓, HSP70/HSPA5↓, HSP90↓, TumCCA↑, angioG↓,
3369- QC,    Pharmacological basis and new insights of quercetin action in respect to its anti-cancer effects
- Review, Pca, NA
FAK↓, TumCCA↑, p‑pRB↓, CDK2↑, CycB/CCNB1↓, CDK1↓, EMT↓, PI3K↓, MAPK↓, Wnt↓, ROS↑, miR-21↑, Akt↓, NF-kB↓, FasL↑, Bak↑, BAX↑, Bcl-2↓, Casp3↓, Casp9↑, P53↑, p38↑, MAPK↑, Cyt‑c↑, PARP↓, CHOP↑, ROS↓, LDH↑, GRP78/BiP↑, ERK↑, MDA↓, SOD↑, GSH↑, NRF2↑, VEGF↓, PDGF↓, EGF↓, FGF↓, TNF-α↓, TGF-β↓, VEGFR2↓, EGFR↓, FGFR1↓, mTOR↓, cMyc↓, MMPs↓, LC3B-II↑, Beclin-1↑, IL1β↓, CRP↓, IL10↓, COX2↓, IL6↓, TLR4↓, Shh↓, HER2/EBBR2↓, NOTCH↓, DR5↑, HSP70/HSPA5↓, CSCs↓, angioG↓, MMP2↓, MMP9↓, IGFBP3↑, uPA↓, uPAR↓, RAS↓, Raf↓, TSP-1↑,
3368- QC,    The potential anti-cancer effects of quercetin on blood, prostate and lung cancers: An update
- Review, Var, NA
*Inflam↓, *antiOx↑, *AntiCan↑, Casp3↓, p‑Akt↓, p‑mTOR↓, p‑ERK↓, β-catenin/ZEB1↓, Hif1a↓, AntiAg↓, VEGFR2↓, EMT↓, EGFR↓, MMP2↓, MMP↓, TumMeta↓, MMPs↓, Akt↓, Snail↓, N-cadherin↓, Vim↓, E-cadherin↑, STAT3↓, TGF-β↓, ROS↓, P53↑, BAX↑, PKCδ↓, PI3K↓, COX2↓, cFLIP↓, cycD1/CCND1↓, cMyc↓, IL6↓, IL10↓, Cyt‑c↑, TumCCA↑, DNMTs↓, HDAC↓, ac‑H3↑, ac‑H4↑, Diablo↑, Casp3↑, Casp9↑, PARP1↑, eff↑, PTEN↑, VEGF↓, NO↓, iNOS↓, ChemoSen↑, eff↑, eff↑, eff↑, uPA↓, CXCR4↓, CXCL12↓, CLDN2↓, CDK6↓, MMP9↓, TSP-1↑, Ki-67↓, PCNA↓, ROS↑, ER Stress↑,
3198- SFN,    Sulforaphane and TRAIL induce a synergistic elimination of advanced prostate cancer stem-like cells
- in-vitro, Pca, NA
Nanog↓, SOX2↓, E-cadherin↓, Snail↓, VEGFR2↓, Diff↓, TumCMig↓, EMT↓, CXCR4↓, NOTCH1↓, ALDH1A1↓, CSCs↓, eff↑,
1434- SFN,  GEM,    Sulforaphane Potentiates Gemcitabine-Mediated Anti-Cancer Effects against Intrahepatic Cholangiocarcinoma by Inhibiting HDAC Activity
- in-vitro, CCA, HuCCT1 - in-vitro, CCA, HuH28 - in-vivo, NA, NA
HDAC↓, ac‑H3↑, ChemoSen↑, tumCV↓, TumCP↓, TumCCA↑, Apoptosis↑, cl‑Casp3↑, TumCI↓, VEGF↓, VEGFR2↓, Hif1a↓, eNOS↓, EMT?, TumCG↓, Ki-67↓, TUNEL↑, P21↑, p‑Chk2↑, CDC25↓, BAX↑, *ROS↓, NQO1?,
3288- SIL,    Silymarin in cancer therapy: Mechanisms of action, protective roles in chemotherapy-induced toxicity, and nanoformulations
- Review, Var, NA
Inflam↓, lipid-P↓, TumMeta↓, angioG↓, chemoP↑, EMT↓, HDAC↓, HATs↑, MMPs↓, uPA↓, PI3K↓, Akt↓, VEGF↓, CD31↓, Hif1a↓, VEGFR2↓, Raf↓, MEK↓, ERK↓, BIM↓, BAX↑, Bcl-2↓, Bcl-xL↓, Casp↑, MAPK↓, P53↑, LC3II↑, mTOR↓, YAP/TEAD↓, *BioAv↓, MMP↓, Cyt‑c↑, PCNA↓, cMyc↓, cycD1/CCND1↓, β-catenin/ZEB1↓, survivin↓, APAF1↑, Casp3↑, MDSCs↓, IL10↓, IL2↑, IFN-γ↑, hepatoP↑, cardioP↑, GSH↑, neuroP↑,
3427- TQ,    Chemopreventive and Anticancer Effects of Thymoquinone: Cellular and Molecular Targets
ROS⇅, Fas↑, DR5↑, TRAIL↑, Casp3↑, Casp8↑, Casp9↑, P53↑, mTOR↓, Bcl-2↓, BID↓, CXCR4↓, JNK↑, p38↑, MAPK↑, LC3II↑, ATG7↑, Beclin-1↑, AMPK↑, PPARγ↑, eIF2α↓, P70S6K↓, VEGF↓, ERK↓, NF-kB↓, XIAP↓, survivin↓, p65↓, DLC1↑, FOXO↑, TET2↑, CYP1B1↑, UHRF1↓, DNMT1↓, HDAC1↓, IL2↑, IL1↓, IL6↓, IL10↓, IL12↓, TNF-α↓, iNOS↓, COX2↓, 5LO↓, AP-1↓, PI3K↓, Akt↓, cMET↓, VEGFR2↓, CXCL1↓, ITGA5↓, Wnt↓, β-catenin/ZEB1↓, GSK‐3β↓, Myc↓, cycD1/CCND1↓, N-cadherin↓, Snail↓, Slug↓, Vim↓, Twist↓, Zeb1↓, MMP2↓, MMP7↓, MMP9↓, JAK2↓, STAT3↓, NOTCH↓, cycA1/CCNA1↓, CDK2↓, CDK4↓, CDK6↓, CDC2↓, CDC25↓, Mcl-1↓, E2Fs↓, p16↑, p27↑, P21↑, ChemoSen↑,
3422- TQ,    Thymoquinone, as a Novel Therapeutic Candidate of Cancers
- Review, Var, NA
selectivity↑, P53↑, PTEN↑, NF-kB↓, PPARγ↓, cMyc↓, Casp↑, *BioAv↓, BioAv↝, eff↑, survivin↓, Bcl-xL↓, Bcl-2↓, Akt↓, BAX↑, cl‑PARP↑, CXCR4↓, MMP9↓, VEGFR2↓, Ki-67↓, COX2↓, JAK2↓, cSrc↓, Apoptosis↑, p‑STAT3↓, cycD1/CCND1↓, Casp3↑, Casp7↑, Casp9↑, N-cadherin↓, Vim↓, Twist↓, E-cadherin↑, ChemoSen↑, eff↑, EMT↓, ROS↑, DNMT1↓, eff↑, EZH2↓, hepatoP↑, Zeb1↓, RadioS↑, HDAC↓, HDAC1↓, HDAC2↓, HDAC3↓, *NAD↑, *SIRT1↑, SIRT1↓, *Inflam↓, *CRP↓, *TNF-α↓, *IL6↓, *IL1β↓, *eff↑, *MDA↓, *NO↓, *GSH↑, *SOD↑, *Catalase↑, *GPx↑, PI3K↓, mTOR↓,

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 29

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

antiOx⇅, 1,   CYP1A1↓, 1,   Fenton↑, 1,   GSH↓, 1,   GSH↑, 2,   GSTs↑, 1,   H2O2↓, 1,   H2O2↑, 1,   HO-1↓, 2,   lipid-P↓, 1,   MAD↓, 1,   MDA↓, 1,   NQO1?, 1,   NRF2↓, 1,   NRF2↑, 4,   p‑NRF2↓, 1,   ROS↓, 2,   ROS↑, 13,   ROS⇅, 1,   i-ROS↑, 1,   mt-ROS↑, 1,   SIRT3↑, 1,   SOD↑, 1,   TrxR↓, 1,  

Mitochondria & Bioenergetics ⓘ

ATP↓, 1,   CDC2↓, 3,   CDC25↓, 3,   EGF↓, 1,   FGFR1↓, 1,   MEK↓, 2,   MMP↓, 8,   MPT↑, 1,   mtDam↑, 1,   OCR↓, 1,   Raf↓, 3,   c-Raf↓, 1,   XIAP↓, 4,  

Core Metabolism/Glycolysis ⓘ

AMPK↑, 4,   ATG7↑, 2,   cMyc↓, 7,   p‑cMyc↑, 1,   FASN↓, 1,   GlucoseCon↓, 1,   Glycolysis↓, 4,   HK2↓, 1,   lactateProd↓, 1,   LDH↓, 1,   LDH↑, 1,   LDHA↓, 1,   PCK1↓, 1,   PDH↝, 1,   PDK1↓, 1,   PKM2↓, 1,   PPARγ↓, 2,   PPARγ↑, 2,   p‑S6K↓, 1,   SIRT1↓, 2,  

Cell Death ⓘ

Akt↓, 17,   p‑Akt↓, 3,   APAF1↑, 1,   Apoptosis↑, 8,   ASK1↑, 1,   Bak↑, 1,   BAX↑, 11,   Bax:Bcl2↑, 2,   Bcl-2↓, 11,   Bcl-xL↓, 3,   BID↓, 1,   BIM↓, 1,   Casp↑, 5,   Casp12↑, 1,   Casp3↓, 2,   Casp3↑, 10,   cl‑Casp3↑, 2,   Casp7↑, 1,   Casp8↑, 2,   cl‑Casp8↑, 1,   Casp9↑, 10,   cl‑Casp9↑, 1,   cFLIP↓, 1,   Chk2↑, 1,   p‑Chk2↑, 1,   Cyt‑c↑, 10,   Diablo↑, 2,   DR4↑, 1,   DR5↑, 8,   FADD↑, 1,   Fas↑, 6,   FasL↑, 1,   Hippo↓, 1,   hTERT/TERT↓, 1,   IAP2↓, 1,   iNOS↓, 3,   JNK↑, 6,   MAPK↓, 8,   MAPK↑, 3,   Mcl-1↓, 3,   Mcl-1↑, 1,   MDM2↓, 1,   Myc↓, 1,   NICD↓, 1,   p27↑, 4,   p38↑, 4,   p‑p38↓, 1,   survivin↓, 8,   Telomerase↓, 2,   TRAIL↑, 1,   TUNEL↑, 1,   YAP/TEAD↓, 2,   YAP/TEAD↑, 1,  

Kinase & Signal Transduction ⓘ

cSrc↓, 1,   EF-1α↓, 1,   HER2/EBBR2↓, 1,   Sp1/3/4↓, 1,  

Transcription & Epigenetics ⓘ

cJun↑, 1,   EZH2↓, 1,   H3↑, 1,   p‑H3↓, 1,   ac‑H3↑, 2,   H4↑, 1,   ac‑H4↑, 1,   HATs↑, 2,   miR-21↑, 1,   other↓, 1,   p‑pRB↓, 1,   tumCV↓, 1,  

Protein Folding & ER Stress ⓘ

CHOP↑, 2,   cl‑CHOP↑, 1,   eIF2α↓, 1,   ER Stress↑, 6,   GRP78/BiP↑, 3,   HSP70/HSPA5↓, 3,   HSP90↓, 1,  

Autophagy & Lysosomes ⓘ

ATG5↑, 2,   Beclin-1↑, 4,   LC3B-II↑, 2,   LC3II↑, 4,   LC3s↑, 1,   TumAuto↑, 5,  

DNA Damage & Repair ⓘ

ATM↑, 1,   CHK1↓, 1,   CHK1↑, 1,   CYP1B1↑, 1,   DNAdam↑, 4,   DNMT1↓, 2,   DNMTs↓, 1,   p16↑, 1,   P53↓, 1,   P53↑, 10,   PARP↓, 1,   cl‑PARP↑, 7,   PARP1↑, 1,   PCNA↓, 5,   TP53↑, 1,   UHRF1↓, 1,  

Cell Cycle & Senescence ⓘ

CDK1↓, 1,   CDK2↓, 7,   CDK2↑, 2,   CDK4↓, 5,   cycA1/CCNA1↓, 1,   CycB/CCNB1↓, 3,   cycD1/CCND1↓, 10,   cycE/CCNE↓, 2,   E2Fs↓, 1,   P21?, 1,   P21↑, 7,   p‑RB1↓, 1,   TumCCA↑, 13,  

Proliferation, Differentiation & Cell State ⓘ

4E-BP1↓, 1,   ALDH1A1↓, 1,   CD133↓, 2,   CD44↓, 1,   CIP2A↓, 1,   cMET↓, 1,   CSCs↓, 5,   Diff↓, 2,   Diff↑, 1,   EMT?, 1,   EMT↓, 11,   ERK↓, 7,   ERK↑, 1,   p‑ERK↓, 1,   FGF↓, 1,   FOXO↓, 1,   FOXO↑, 1,   Gli1↓, 1,   GSK‐3β↓, 1,   GSK‐3β↑, 1,   p‑GSK‐3β↓, 1,   HDAC↓, 5,   HDAC1↓, 2,   HDAC2↓, 1,   HDAC3↓, 1,   HH↓, 1,   IGF-1↓, 1,   IGFBP3↑, 1,   IGFR↓, 1,   mTOR↓, 6,   p‑mTOR↓, 2,   mTORC1↓, 2,   p‑mTORC1↓, 1,   mTORC2↓, 1,   n-MYC↓, 1,   Nanog↓, 2,   Nestin↓, 2,   NOTCH↓, 6,   NOTCH1↓, 3,   NOTCH3↓, 1,   OCT4↓, 2,   P70S6K↓, 2,   PI3K↓, 14,   PTEN↑, 4,   RAS↓, 3,   Shh↓, 2,   Smo↓, 1,   SOX2↓, 4,   STAT1↓, 1,   STAT3↓, 10,   p‑STAT3↓, 2,   TAZ↓, 1,   TOP1↓, 1,   TOP2↓, 2,   TumCG↓, 4,   Wnt↓, 6,  

Migration ⓘ

5LO↓, 1,   AEG1↓, 1,   AntiAg↓, 1,   AP-1↓, 2,   AXL↓, 1,   CA↓, 1,   Ca+2↑, 5,   CAFs/TAFs↓, 1,   CD31↓, 2,   CLDN2↓, 1,   CXCL12↓, 1,   DLC1↑, 1,   E-cadherin↓, 2,   E-cadherin↑, 8,   FAK↓, 2,   p‑FAK↓, 1,   Fibronectin↓, 1,   ITGA5↓, 1,   Ki-67↓, 6,   MMP1↓, 2,   MMP13↓, 1,   MMP2↓, 11,   MMP7↓, 2,   MMP9↓, 14,   MMPs↓, 6,   N-cadherin↓, 6,   NEDD9↓, 1,   PDGF↓, 3,   PKCδ↓, 3,   Rho↓, 1,   Slug↓, 2,   SMAD3↓, 1,   Snail?, 1,   Snail↓, 6,   SOX4↓, 1,   TGF-β↓, 4,   TGF-β↑, 1,   TIMP1↓, 1,   TIMP1↑, 1,   TIMP2↓, 1,   TIMP2↑, 1,   TSP-1↑, 2,   TumCI↓, 5,   TumCMig↓, 5,   TumCP↓, 6,   TumMeta↓, 8,   Twist↓, 5,   uPA↓, 7,   uPAR↓, 1,   Vim↓, 6,   Zeb1↓, 4,   ZEB2↓, 1,   ZO-1↑, 1,   β-catenin/ZEB1↓, 7,   β-catenin/ZEB1↑, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 13,   EGFR↓, 5,   eNOS↓, 1,   EPR↑, 1,   Hif1a↓, 13,   NO↓, 1,   NO↑, 1,   PDGFR-BB↑, 1,   VEGF↓, 16,   VEGFR2↓, 27,  

Barriers & Transport ⓘ

GLUT1↓, 2,   P-gp↓, 2,  

Immune & Inflammatory Signaling ⓘ

CCR7↓, 1,   COX2↓, 9,   CRP↓, 1,   CXCL1↓, 1,   CXCR4↓, 7,   IFN-γ↓, 1,   IFN-γ↑, 1,   IKKα↓, 1,   IL1↓, 1,   IL10↓, 4,   IL12↓, 1,   IL1β↓, 1,   IL2↑, 2,   IL4↓, 1,   IL6↓, 5,   IL8↓, 1,   IL8↑, 1,   Inflam↓, 3,   JAK1↓, 1,   JAK2↓, 3,   M2 MC↓, 1,   MCP1↓, 1,   MDSCs↓, 1,   NF-kB↓, 14,   p‑NF-kB↑, 1,   p65↓, 2,   PD-1↓, 1,   PGE2↓, 3,   TLR4↓, 1,   TNF-α↓, 3,  

Hormonal & Nuclear Receptors ⓘ

AR↓, 2,   CDK6↓, 5,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 1,   BioAv↝, 1,   ChemoSen↓, 1,   ChemoSen↑, 11,   CYP1A2↓, 1,   Dose?, 1,   Dose↓, 1,   Dose↑, 1,   Dose↝, 3,   eff↑, 22,   eff↝, 1,   Half-Life↓, 2,   Half-Life↝, 1,   MDR1↓, 1,   P450↓, 1,   RadioS↑, 4,   selectivity↑, 4,   TET2↑, 1,  

Clinical Biomarkers ⓘ

AR↓, 2,   CRP↓, 1,   EGFR↓, 5,   EZH2↓, 1,   HER2/EBBR2↓, 1,   hTERT/TERT↓, 1,   IL6↓, 5,   Ki-67↓, 6,   LDH↓, 1,   LDH↑, 1,   Myc↓, 1,   TP53↑, 1,  

Functional Outcomes ⓘ

AntiCan↑, 3,   AntiTum↑, 2,   cardioP↑, 1,   chemoP↑, 4,   ChemoSideEff↓, 1,   hepatoP↑, 3,   neuroP↑, 2,   OS↑, 1,   radioP↑, 1,   RenoP↑, 1,   TumVol↓, 1,  
Total Targets: 364

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 7,   Catalase↑, 2,   GPx↑, 1,   GSH↑, 3,   GSR↑, 1,   GSTA1↑, 1,   GSTs↑, 1,   HNE↓, 1,   HO-1↑, 1,   Keap1↓, 1,   lipid-P↓, 2,   MDA↓, 3,   MPO↓, 1,   NOX4↓, 1,   NRF2↑, 2,   ROS↓, 7,   SOD↑, 5,   TBARS↓, 1,  

Metal & Cofactor Biology ⓘ

IronCh↑, 2,  

Core Metabolism/Glycolysis ⓘ

ALAT↓, 2,   H2S↑, 1,   LDH↓, 2,   LDH↑, 1,   NAD↑, 1,   SIRT1↑, 1,  

Cell Death ⓘ

Akt↓, 1,   iNOS↓, 1,  

Transcription & Epigenetics ⓘ

other↓, 1,   other↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

FGF↑, 1,   PI3K↓, 1,  

Migration ⓘ

5LO↓, 1,   ITGB1↑, 1,   MMP2↓, 1,   MMP9↓, 1,  

Angiogenesis & Vasculature ⓘ

angioG↑, 1,   Hif1a↑, 1,   NO↓, 2,   VEGF↓, 1,   VEGF↑, 1,   VEGFR2↑, 1,   p‑VEGFR2↓, 1,  

Barriers & Transport ⓘ

BBB↑, 2,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 2,   CRP↓, 2,   IL1β↓, 2,   IL6↓, 4,   Imm↑, 1,   Inflam↓, 7,   NF-kB↓, 1,   PGE2↓, 1,   TNF-α↓, 4,  

Synaptic & Neurotransmission ⓘ

GABA↝, 1,  

Protein Aggregation ⓘ

Aβ↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 3,   BioAv↑, 1,   Dose↝, 1,   eff↑, 4,   Half-Life↝, 1,  

Clinical Biomarkers ⓘ

ALAT↓, 2,   AST↓, 2,   BP↓, 1,   creat↓, 1,   CRP↓, 2,   GutMicro↑, 1,   IL6↓, 4,   LDH↓, 2,   LDH↑, 1,  

Functional Outcomes ⓘ

AntiAge↑, 1,   AntiCan↑, 1,   cardioP↑, 2,   cognitive↑, 2,   hepatoP↑, 2,   memory↑, 1,   neuroP↑, 5,   toxicity↓, 2,   toxicity∅, 2,  

Infection & Microbiome ⓘ

Sepsis↓, 1,  
Total Targets: 78

Scientific Paper Hit Count for: VEGFR2, Vascular Endothelial Growth Factor Receptor 2
3 Magnetic Fields
2 Berberine
2 Ellagic acid
2 EGCG (Epigallocatechin Gallate)
2 Luteolin
2 Quercetin
2 Sulforaphane (mainly Broccoli)
2 Thymoquinone
1 Allicin (mainly Garlic)
1 Apigenin (mainly Parsley)
1 Artemisinin
1 Baicalein
1 Boswellia (frankincense)
1 Carnosine
1 Fisetin
1 Grapeseed extract
1 Proanthocyanidins
1 Honokiol
1 HydroxyTyrosol
1 Magnolol
1 Gemcitabine (Gemzar)
1 Silymarin (Milk Thistle) silibinin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:768  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page